On May 20, 2020, CV Sciences, Inc. (the “Company”) issued a press release announcing its plan to adjourn and reconvene its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). The Company will adjourn the Annual Meeting before any of the proposals set forth in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on March 31, 2020, are voted upon. The adjourned Annual Meeting will reconvene on June 16, 2020 at 10:00 a.m., Pacific Time, and will be held virtually. Stockholders of record on March 23, 2020 may attend the reconvened Annual Meeting online, including to vote and/or submit questions as provided in the press release.

A copy of the press release announcing the Company’s plan to adjourn the Annual Meeting is attached hereto as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits

99.1 Press Release of CV Sciences, Inc., dated May 20, 2020

CV Sciences, Inc. Exhibit
EX-99.1 2 pressreleaseofcvsciencesin.htm EXHIBIT 99.1 Exhibit Exhibit 99.1CV SCIENCES,…
To view the full exhibit click here

About CV SCIENCES, INC. (OTCMKTS:CVSI)

CV Sciences, Inc. is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.